Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, a potent biological mediator, today announced that Maurice Zauderer, PhD, Chief Executive Officer, presented new and promising data from continued analysis of final results of the phase 2 SIGNAL Huntington’s Disease Trial at the European Huntington Disease Network Meeting (EHDN2021), which was held September 9-11, 2021.
Plenary Session and Panel Discussion
On September 10, Dr. Zauderer joined clinical leaders from Roche, Wave, Uniqure and Prilenia to discuss major lessons and continuing plans for clinical trials in Huntington’s disease (HD). Dr. Zauderer highlighted new data from the SIGNAL phase 2 trial believed to further support the cognitive benefit of treatment with the pepinemab antibody. People with HD regularly identify cognitive impairment as a major concern that significantly impacts their daily life.
Dr. Zauderer also presented subgroup analysis suggesting that the greatest benefit from treatment was detected in patients with moderately advanced disease and discussed how these findings will impact the design of a planned pivotal phase 3 trial, for which the company is actively evaluating potential development partners.
During the panel discussion that followed, Dr. Zauderer discussed how he believed the results of SIGNAL and other Vaccinex studies have advanced the company’s understanding of pathogenic mechanisms and help to lay a foundation for optimal timing of treatment and identifying rational combination therapies that may result in even greater efficacy in the future. Vaccinex is grateful to the individuals and their families who participated in the SIGNAL phase 2 study and remains committed to advancing this promising potential therapy in both HD and Alzheimer’s disease.
Dr. Zauderer’s video presentation is available here.
About the SIGNAL trial
SIGNAL was a phase 2, multi-center, randomized, double-blinded, placebo-controlled clinical trial in subjects with early manifest and late prodromal HD to assess safety, tolerability, pharmacokinetics, and efficacy of pepinemab. The study included 179 subjects with early manifest disease and 89 subjects diagnosed as late prodromal. Individuals were randomized 1:1 for monthly intravenous infusion with either 20 mg/kg pepinemab or placebo for at least 18 months. The study is now complete and a phase 3 study is being planned to expand on promising data pointing to cognitive benefits of treatment with pepinemab.
Source: Vaccinex
